Skip to main content
915 TLDR
Health
1 read

Trump Signs Order to Boost Psychedelic Research for Mental Health Treatments

KVIACNN Newsource
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

Read Original

AI Summary

President Donald Trump has signed a decree aimed at advancing research on psychedelic drugs, particularly ibogaine, to explore new treatments for mental health issues. The initiative includes a $50 million federal investment and aims to eliminate legal barriers for researchers studying these substances. Trump emphasized the potential of psychedelics to transform the lives of individuals suffering from severe mental illnesses, including veterans. Health officials expect that the approval process for these treatments could be expedited significantly, potentially within weeks. However, concerns have been raised about the safety and regulatory standards of such fast-tracked research.

Key Details: • Federal investment of $50 million allocated for psychedelic research. • Ibogaine is the primary psychedelic mentioned in the decree. • FDA may approve treatments in weeks instead of over a year. • Concerns exist regarding the safety and regulation of accelerated research.

healthcare trump mental-health psychedelics ibogaine

People & Organizations

Donald TrumpFDARobert F. Kennedy Jr.Department of Health and Human ServicesJoe RoganMarty Makary

Related Articles